NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Swedish Ibrance Registries Insights (SIRI)

RecruitingN/A

Sponsor: Pfizer

Conditions: Malignant Neoplasm of Breast

Interventions: palbociclib

Countries: Sweden

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
2. Age ≥18 years at index date

Exclusion Criteria:

There are no exclusion criteria

Locations (1)

Sollentuna, Sweden